36C24520Q0080-001.docx

36C24520Q0080

PAGE 1 OF

1. REQUISITION NO.

2. CONTRACT NO.

3. AWARD/EFFECTIVE DATE

4. ORDER NO.

5. SOLICITATION NUMBER

6. SOLICITATION ISSUE DATE

a. NAME

b. TELEPHONE NO. (No Collect Calls)

8. OFFER DUE DATE/LOCAL

TIME

9. ISSUED BY

CODE

10. THIS ACQUISITION IS

UNRESTRICTED OR

SET ASIDE:

% FOR:

SMALL BUSINESS

HUBZONE SMALL

BUSINESS

SERVICE-DISABLED

VETERAN-OWNED

SMALL BUSINESS

WOMEN-OWNED SMALL BUSINESS

(WOSB) ELIGIBLE UNDER THE WOMEN-OWNED

SMALL BUSINESS PROGRAM

EDWOSB

8(A)

NAICS:

SIZE STANDARD:

11. DELIVERY FOR FOB DESTINA-

TION UNLESS BLOCK IS

MARKED

SEE SCHEDULE

12. DISCOUNT TERMS

13a. THIS CONTRACT IS A

RATED ORDER UNDER

DPAS (15 CFR 700)

13b. RATING

14. METHOD OF SOLICITATION

RFQ

IFB

RFP

15. DELIVER TO

CODE

16. ADMINISTERED BY

CODE

17a. CONTRACTOR/OFFEROR

CODE

FACILITY CODE

18a. PAYMENT WILL BE MADE BY

CODE

TELEPHONE NO.

DUNS:

DUNS+4:

PHONE:

FAX:

17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER 18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED

SEE ADDENDUM

19.

20.

21.

22.

23.

24.

ITEM NO.

SCHEDULE OF SUPPLIES/SERVICES

QUANTITY

UNIT

UNIT PRICE

AMOUNT

(Use Reverse and/or Attach Additional Sheets as Necessary)

25. ACCOUNTING AND APPROPRIATION DATA

26. TOTAL AWARD AMOUNT (For Govt. Use Only) 27a. SOLICITATION INCORPORATES BY REFERENCE FAR 52.212-1, 52.212-4. FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED.

27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED

28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN _______________

29. AWARD OF CONTRACT: REF. ___________________________________ OFFER

COPIES TO ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND

DATED ________________________________. YOUR OFFER ON SOLICITATION

DELIVER ALL ITEMS SET FORTH OR OTHERWISE IDENTIFIED ABOVE AND ON ANY

(BLOCK 5), INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE

ADDITIONAL SHEETS SUBJECT TO THE TERMS AND CONDITIONS SPECIFIED

SET FORTH HEREIN IS ACCEPTED AS TO ITEMS:

30a. SIGNATURE OF OFFEROR/CONTRACTOR 31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER) 30b. NAME AND TITLE OF SIGNER (TYPE OR PRINT) 30c. DATE SIGNED 31b. NAME OF CONTRACTING OFFICER (TYPE OR PRINT) 31c. DATE SIGNED

AUTHORIZED FOR LOCAL REPRODUCTION

(REV. 2/2012)

PREVIOUS EDITION IS NOT USABLE

Prescribed by GSA - FAR (48 CFR) 53.212

7. FOR SOLICITATION

INFORMATION CALL:

STANDARD FORM 1449

OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEMS

512-20-1-027-0001 36C24520Q0080 03-17-2020 Keysha Hill 410-637-1509 03-27-2020 Noon Department of Veterans Affairs

VAMC

209 West Fayette Street Baltimore

MD

21201 X X 621511 $35 Million N/A X Department of Veterans Affairs VAMC(512) Warehouse 209 West Fayette Street Baltimore

MD

21201 Department of Veterans Affairs

VAMC

209 West Fayette Street Baltimore

MD

21201

PAYMENT WILL BE MADE BY

FSC e-Invoice Payment Invoice must be submitted electronically http://www.fsc.va.gov/einvoice.asp Invoice Setup Information 1-877-489-6135

See CONTINUATION Page The Department of Veterans Affairs are seeking Urine Toxicology Testing. See Statement of Work for a detail description of what type of services needed.

Questions are due by 3/22/2020 noon. Email them to Keysha.Hill@va.gov See CONTINUATION Page x X Kristine Stout Table of Contents

SECTION B - CONTINUATION OF SF 1449 BLOCKS

B.1 CONTRACT ADMINISTRATION DATA

1. Contract Administration: All contract administration matters will be handled by the following individuals:

a. CONTRACTOR:

b. GOVERNMENT: Contracting Officer 36C245 Keysha Hill Department of Veterans Affairs

VAMC

209 West Fayette Street Baltimore MD 21201

2. CONTRACTOR REMITTANCE ADDRESS: All payments by the Government to the contractor will be made in accordance with:

3. INVOICES: Invoices shall be submitted in arrears:

4. GOVERNMENT INVOICE ADDRESS: All Invoices from the contractor shall be submitted electronically in accordance with VAAR Clause 852.232-72 Electronic Submission of Payment Requests.

PAYMENT WILL BE MADE BY

FSC e-Invoice Payment Invoice must be submitted electronically http://www.fsc.va.gov/einvoice.asp Invoice Setup Information 1-877-489-6135 ACKNOWLEDGMENT OF AMENDMENTS: The offeror acknowledges receipt of amendments to the Solicitation numbered and dated as follows:

STATEMENT OF WORK

The Pathology and Laboratory Medicine Service requires urine toxicology testing to be performed under a new base plus four option year contract. The contractor shall provide all labor, supplies, equipment, maintenance, information technology, and supervision necessary to provide Reference Laboratory Services to VAMHC-Baltimore described herein. Reference Laboratory Services include but are not limited to: specimen preparation and storage; transportation of clinical laboratory specimens; performance of analytical testing; reporting of analytical test results and consultative services. This contract will be an IDIQ (Indefinite Delivery Indefinite Quantity) Contract covers monthly invoicing for urine toxicology testing from April 1, 2020 through September 30, 2024. The one-time guaranteed minimum order amount is $1000.00. The total of all orders awarded under this IDIQ shall not exceed $500,000.00. The following test(s) are included:

1. Opiates

2. Cocaine

3. Benzodiazepines

4.PCP

5.THC (cannabinoids)

6. Amphetamines

7. Methamphetamines

8. Oxycodone

9. Buprenorphine 10.Methadone

11. Fentanyl LC/MS Confirmation

Specimen Preparation and Storage for Reference Testing Specimens

a. Contractor shall supply the Government facility with its commercial laboratory reference test manual to insure the collection and storage of specimens are in accordance with Contractor’s requirements.

b. Contractor shall be responsible for storing specimens in such a manner to insure the integrity of the specimen

Transportation Services for Reference Testing Specimens

a. Contractor shall provide transportation of primarily biomedical materials that include patient specimens, originating from Government facilities and destined to the contracted commercial reference laboratory. These items are classified as Hazard Materials Class 6, Division 6.2 and are defined in 49 CFR Part 173.134 as those materials that contain or could contain etiologic agents. Transportation shall be done in such a manner that the safety and integrity of the biomedical material is maintained.

b. Specimen pick-up will be requested via phone from Monday through Friday, only as needed, and with no additional cost to the government. Specimens will be picked up by the vendor, no later than 12pm of the business day following the request. Specimens will not contain any patient Personally-Identifiable- Information (PII) and will be identified only by VA accession number.

c. Contractor shall provide all necessary supplies for biomedical materials to be transported from the originating facility to the Contractor’s laboratory. These supplies shall include, but may not be limited to:

1. Shipping and packaging containers. Packing material must be capable of maintaining temperature requirements for specimens until they reach the Contractor’s laboratory.

2. Required labels and packaging materials for shipping specimens via courier that are infectious, or etiologic agents, in accordance with appropriate requirements of 42 CFR Part 72, 49 CFR Parts 171 and 173, and the Dangerous Goods Regulations of the International Air Transport Association (IATA) consistent with current regulatory updates.

3. Any required test request forms preprinted with the appropriate Shipping Section details and account information.

4. Test request forms for specialized testing (i.e. cytogenetics, tissue, etc.).

Specimen Testing

a. The Contractor and/or subcontractor shall provide the full range of clinical and anatomic pathology diagnostic testing capabilities to execute all required tests listed in the CLINS. Contractor shall make available the following test information:

1. Requisition form requirements

2. Alphabetized test name list

3. Test order code

4. Specimen collection and preservation requirements

5. Test method employed (indicate if testing performed in duplicate) and interpretations

6. Test reference intervals adjusted for age, sex or race, when required

7. Test specific sensitivity, specificity and interferences, when required

8. Result code

9. Test critical values, if any

10. Policy for critical value notification

11. CPT coding

12. Test turnaround times (minimum and maximum times indicated); where the turnaround time is defined as the time between pick-up of specimen by the Contractor and receipt of results by a Government facility.

13. Schedule of test performance (specific days of week indicated)

14. Location of test performance by test name (i.e. name of primary laboratory, name of separate branch/division of primary lab, name and address of secondary (sub-contracted) laboratory must be cited).

b. Contractor shall notify the Contracting Officer and each Government facility of any test information modifications no later than two weeks prior to the implementation date of the test change. Any new test(s) not listed in Attachment A must be added to the contract through modification by the Contracting Officer (CORs and Government facility representatives do not have this authority) prior to specimen being tested.

c. All reference laboratory testing shall be executed in accordance with standard industry practices. It is preferred that test methods are FDA approved. Any non-FDA approved method being performed shall have a disclaimer and documented validation plan. Upon request, the validation plan and validation results shall be made available to the COR or designee.

d. The Contractor shall ensure the accurate and timely performance of laboratory testing services on the biomedical materials.

Reporting of Results

a. The results of testing shall be reported within the prescribed turnaround times provided by the Contractor as part of the test information, but not more than 5 days from being picked up.

b. Results will be sent to the Chemistry Lab Supervisor and the Chemistry Section Chief Pathologist via email for entry into Vista computer system. Note: these results must not contain any PII. Notice for any delays in testing/resulting shall be communicated by telephone to a designated Government contact person(s) at the originating Government laboratory facility.

c. In unusual circumstances where electronic delivery is not possible, the Contractor shall deliver the reports without an additional charge by expedited overnight courier shipping, mailing and/or transportation services by hand within 24 hours, or by telephone facsimile to a protected machine identified to the Contractor by the VA.

d. Each test report shall, at minimum, include the following information:

1. Government laboratory accession number

2. Submitting facility name

3. Submitting facility account number

4. Patient's location (clinic/ward)

5. Test(s) ordered

6. Date/time of specimen collection

7. Date/time test completed

8. Test result

9. Reference intervals (adjusted for age, sex or race, when appropriate) 10.Toxic and therapeutic ranges, if applicable 11.Flagged abnormal results 12.Reference laboratory accession number 13.Name and address of testing laboratory 14.Any other information the laboratory has that may indicate a questionable validity of test results.

15.Specimen inadequacy shall be reported with documentation supporting its unsuitability for testing.

e. Test results determined by the contractor to be critical, shall be communicated by telephone to a designated Government contact person(s) at the originating Government laboratory facility upon verification of the critical test result. The telephonic report shall be followed by an electronic transmission.

f. Invoicing for testing performed will be sent on a monthly basis through the OB10/IPPS Fiscal portal.

Customer Service

a. Contractor shall provide customer service that is accessible by toll-free telephone service 24 hours per day, 7 days per week to assist Government staff for tracking and resolving related issues/problems that may arise in the performance under this contract.

b. Upon award, the Contractor shall provide the name(s) and telephone number(s) of contractor employees who will address the following customer services throughout the contract performance period:

1. Telephone Inquiries – Telephone inquiries are divided into four major categories with additional subcategories defining the type of inquiry and the Government’s minimum time expectation for meeting this service.

Specimen Collection

a. Routine inquiries, questions and clarifications regarding collection requirements shall be addressed at the time of the initial call.

b. Esoteric inquiries, questions and clarifications regarding collection requirements that require further research shall be addressed within ½ hour of the initial call.

Testing

a. Inquiries regarding the status of pending orders shall be addressed at the time of the initial call.

b. Esoteric inquiries when information is requested regarding methodology, correlation, interferences, reflex tests, etc. shall be addressed within two hours of the initial call.

Technical Expertise

a. Test utilization inquiries where information is required as to the most appropriate test to be ordered shall be addressed within two business hours of initial call.

b. Result interpretation inquiries shall be addressed within four business hours of initial call.

c. Consultative services where information is required regarding the clinical significance of tests shall be addressed within twenty-four business hours of the initial call.

Account follow-up

a. Information general in nature yet specific to the account, e.g. test pricing, equipment repair, supply ordering, etc. shall be addressed within four hours of the initial call.

b. The Contractor shall notify the originating laboratory by telephone of specimens cancelled due to unacceptability for reasons relating to volume, specimen container, identification, loss of specimen, etc.

B.2 PRICE/COST SCHEDULE

ITEM INFORMATION

6 MONOACETYL MORPHINE (GC/MS)

Contract Period: Base POP Begin: 04-01-2020 POP End: 09-30-2020 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical- Laboratory Testing

AMPHETAMINES (LC/MS)

POP Begin: 04-01-2020 POP End: 09-30-2020

BARBITURATES LC/MS

POP Begin: 04-01-2020 POP End: 09-30-2020

BENZODIAZEPINES (LC/MS)

POP Begin: 04-01-2020 POP End: 09-30-2020

BENZOYLECOGNINE

POP Begin: 04-01-2020 POP End: 09-30-2020

BUPRENORPHINE CONF (LC/MS)

POP Begin: 04-01-2020 POP End: 09-30-2020

CLONIDINE

POP Begin: 04-01-2020 POP End: 09-30-2020

COCAINE (LC/MS)

POP Begin: 04-01-2020 POP End: 09-30-2020

DELTA 9 THC COOH (GC/MS)

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA BUPRENORPHINE (O.F.)

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA FENTANYL SCREEN (URINE)

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA AMPHETAMINES

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA BARBITURATES

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA BENZODIAZEPINES

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA BUPRENORPHINE

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA BUPRENORPHINE WITH PANEL

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA COCAINE

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA FENTANYL with Panel (URINE)

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA METHADONE (O.F.)

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA OPIATES

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA OXYCODONE/OXYMORPHONE SCREEN WITH PANEL

POP Begin: 04-01-2020 POP End: 09-30-2020

EIA PCP

POP Begin: 04-01-2020 POP End: 09-30-2020

FENTANYL LC/MS CONFIRMATION (URINE)

POP Begin: 04-01-2020 POP End: 09-30-2020

FENTANYL ORAL FLUID CONFIRMATION LC/MS

POP Begin: 04-01-2020 POP End: 09-30-2020

FULL DRUG SCAN (GC/MS)

POP Begin: 04-01-2020 POP End: 09-30-2020

LC/MS/MS OXYCODONE(FFL)

POP Begin: 04-01-2020 POP End: 09-30-2020

METHADONE (LC/MS)

POP Begin: 04-01-2020 POP End: 09-30-2020

OF FENTANYL(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-8 PANEL (EIA)

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-AMPH (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-BENZODIAZEPINES (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-BUPRENORPHINE(LC/MS/MS)-FFL-ORALFLUID CONFIRMATION

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-COCAINE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-METHADONE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-OPIATE (LC/MS/MS) FFL

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-PCP(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 04-01-2020 POP End: 09-30-2020

OF-THC(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 04-01-2020 POP End: 09-30-2020

OPIATES LC/MS (CLINICAL) (URINE)

POP Begin: 04-01-2020 POP End: 09-30-2020

ORAL 6 PANEL (EIA)

POP Begin: 04-01-2020 POP End: 09-30-2020

ORAL FLUID (O,M,C,V,T,OXY,BUP) (EIA)

POP Begin: 04-01-2020 POP End: 09-30-2020

ORAL FLUID 7 PANEL (EIA)

POP Begin: 04-01-2020 POP End: 09-30-2020

Oral Fluid 10 Panel

POP Begin: 04-01-2020 POP End: 09-30-2020

PHENOTHIAZINES (PHENERGAN)

POP Begin: 04-01-2020 POP End: 09-30-2020

RECHECK

POP Begin: 04-01-2020 POP End: 09-30-2020

TLC S2 SCREEN

POP Begin: 04-01-2020 POP End: 09-30-2020

UNTESTABLE

POP Begin: 04-01-2020 POP End: 09-30-2020

UNTESTABLE (B)

POP Begin: 04-01-2020 POP End: 09-30-2020

6 MONOACETYL MORPHINE (GC/MS)

Contract Period: Option 1 POP Begin: 10-01-2020 POP End: 09-30-2021

AMPHETAMINES (LC/MS)

POP Begin: 10-01-2020 POP End: 09-30-2021

BARBITURATES LC/MS

POP Begin: 10-01-2020 POP End: 09-30-2021

BENZODIAZEPINES (LC/MS)

POP Begin: 10-01-2020 POP End: 09-30-2021

BENZOYLECOGNINE

POP Begin: 10-01-2020 POP End: 09-30-2021

BUPRENORPHINE CONF (LC/MS)

POP Begin: 10-01-2020 POP End: 09-30-2021

CLONIDINE

POP Begin: 10-01-2020 POP End: 09-30-2021

COCAINE (LC/MS)

POP Begin: 10-01-2020 POP End: 09-30-2021

DELTA 9 THC COOH (GC/MS)

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA BUPRENORPHINE (O.F.)

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA FENTANYL SCREEN (URINE)

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA AMPHETAMINES

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA BARBITURATES

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA BENZODIAZEPINES

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA BUPRENORPHINE

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA BUPRENORPHINE WITH PANEL

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA COCAINE

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA FENTANYL with Panel (URINE)

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA METHADONE (O.F.)

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA OPIATES

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA OXYCODONE/OXYMORPHONE SCREEN WITH PANEL

POP Begin: 10-01-2020 POP End: 09-30-2021

EIA PCP

POP Begin: 10-01-2020 POP End: 09-30-2021

FENTANYL LC/MS CONFIRMATION (URINE)

POP Begin: 10-01-2020 POP End: 09-30-2021

FENTANYL ORAL FLUID CONFIRMATION LC/MS

POP Begin: 10-01-2020 POP End: 09-30-2021

FULL DRUG SCAN (GC/MS)

POP Begin: 10-01-2020 POP End: 09-30-2021

LC/MS/MS OXYCODONE(FFL)

POP Begin: 10-01-2020 POP End: 09-30-2021

METHADONE (LC/MS)

POP Begin: 10-01-2020 POP End: 09-30-2021

OF FENTANYL(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-8 PANEL (EIA)

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-AMPH (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-BENZODIAZEPINES (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-BUPRENORPHINE(LC/MS/MS)-FFL-ORALFLUID CONFIRMATION

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-COCAINE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-METHADONE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-OPIATE (LC/MS/MS) FFL

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-PCP(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2020 POP End: 09-30-2021

OF-THC(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2020 POP End: 09-30-2021

OPIATES LC/MS (CLINICAL) (URINE)

POP Begin: 10-01-2020 POP End: 09-30-2021

ORAL 6 PANEL (EIA)

POP Begin: 10-01-2020 POP End: 09-30-2021

ORAL FLUID (O,M,C,V,T,OXY,BUP) (EIA)

POP Begin: 10-01-2020 POP End: 09-30-2021

ORAL FLUID 7 PANEL (EIA)

POP Begin: 10-01-2020 POP End: 09-30-2021

Oral Fluid 10 Panel

POP Begin: 10-01-2020 POP End: 09-30-2021

PHENOTHIAZINES (PHENERGAN)

POP Begin: 10-01-2020 POP End: 09-30-2021

RECHECK

POP Begin: 10-01-2020 POP End: 09-30-2021

TLC S2 SCREEN

POP Begin: 10-01-2020 POP End: 09-30-2021

UNTESTABLE

POP Begin: 10-01-2020 POP End: 09-30-2021

UNTESTABLE (B)

POP Begin: 10-01-2020 POP End: 09-30-2021

6 MONOACETYL MORPHINE (GC/MS)

Contract Period: Option 2 POP Begin: 10-01-2021 POP End: 09-30-2022

AMPHETAMINES (LC/MS)

POP Begin: 10-01-2021 POP End: 09-30-2022

BARBITURATES LC/MS

POP Begin: 10-01-2021 POP End: 09-30-2022

BENZODIAZEPINES (LC/MS)

POP Begin: 10-01-2021 POP End: 09-30-2022

BENZOYLECOGNINE

POP Begin: 10-01-2021 POP End: 09-30-2022

BUPRENORPHINE CONF (LC/MS)

POP Begin: 10-01-2021 POP End: 09-30-2022

CLONIDINE

POP Begin: 10-01-2021 POP End: 09-30-2022

COCAINE (LC/MS)

POP Begin: 10-01-2021 POP End: 09-30-2022

DELTA 9 THC COOH (GC/MS)

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA BUPRENORPHINE (O.F.)

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA FENTANYL SCREEN (URINE)

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA AMPHETAMINES

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA BARBITURATES

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA BENZODIAZEPINES

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA BUPRENORPHINE

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA BUPRENORPHINE WITH PANEL

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA COCAINE

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA FENTANYL with Panel (URINE)

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA METHADONE (O.F.)

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA OPIATES

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA OXYCODONE/OXYMORPHONE SCREEN WITH PANEL

POP Begin: 10-01-2021 POP End: 09-30-2022

EIA PCP

POP Begin: 10-01-2021 POP End: 09-30-2022

FENTANYL LC/MS CONFIRMATION (URINE)

POP Begin: 10-01-2021 POP End: 09-30-2022

FENTANYL ORAL FLUID CONFIRMATION LC/MS

POP Begin: 10-01-2021 POP End: 09-30-2022

FULL DRUG SCAN (GC/MS)

POP Begin: 10-01-2021 POP End: 09-30-2022

LC/MS/MS OXYCODONE(FFL)

POP Begin: 10-01-2021 POP End: 09-30-2022

METHADONE (LC/MS)

POP Begin: 10-01-2021 POP End: 09-30-2022

OF FENTANYL(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-8 PANEL (EIA)

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-AMPH (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-BENZODIAZEPINES (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-BUPRENORPHINE(LC/MS/MS)-FFL-ORALFLUID CONFIRMATION

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-COCAINE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-METHADONE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-OPIATE (LC/MS/MS) FFL

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-PCP(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2021 POP End: 09-30-2022

OF-THC(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2021 POP End: 09-30-2022

OPIATES LC/MS (CLINICAL) (URINE)

POP Begin: 10-01-2021 POP End: 09-30-2022

ORAL 6 PANEL (EIA)

POP Begin: 10-01-2021 POP End: 09-30-2022

ORAL FLUID (O,M,C,V,T,OXY,BUP) (EIA)

POP Begin: 10-01-2021 POP End: 09-30-2022

ORAL FLUID 7 PANEL (EIA)

POP Begin: 10-01-2021 POP End: 09-30-2022

Oral Fluid 10 Panel

POP Begin: 10-01-2021 POP End: 09-30-2022

PHENOTHIAZINES (PHENERGAN)

POP Begin: 10-01-2021 POP End: 09-30-2022

RECHECK

POP Begin: 10-01-2021 POP End: 09-30-2022

TLC S2 SCREEN

POP Begin: 10-01-2021 POP End: 09-30-2022

UNTESTABLE

POP Begin: 10-01-2021 POP End: 09-30-2022

UNTESTABLE (B)

POP Begin: 10-01-2021 POP End: 09-30-2022

6 MONOACETYL MORPHINE (GC/MS)

Contract Period: Option 3 POP Begin: 10-01-2022 POP End: 09-30-2023

AMPHETAMINES (LC/MS)

POP Begin: 10-01-2022 POP End: 09-30-2023

BARBITURATES LC/MS

POP Begin: 10-01-2022 POP End: 09-30-2023

BENZODIAZEPINES (LC/MS)

POP Begin: 10-01-2022 POP End: 09-30-2023

BENZOYLECOGNINE

POP Begin: 10-01-2022 POP End: 09-30-2023

BUPRENORPHINE CONF (LC/MS)

POP Begin: 10-01-2022 POP End: 09-30-2023

CLONIDINE

POP Begin: 10-01-2022 POP End: 09-30-2023

COCAINE (LC/MS)

POP Begin: 10-01-2022 POP End: 09-30-2023

DELTA 9 THC COOH (GC/MS)

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA BUPRENORPHINE (O.F.)

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA FENTANYL SCREEN (URINE)

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA AMPHETAMINES

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA BARBITURATES

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA BENZODIAZEPINES

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA BUPRENORPHINE

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA BUPRENORPHINE WITH PANEL

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA COCAINE

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA FENTANYL with Panel (URINE)

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA METHADONE (O.F.)

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA OPIATES

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA OXYCODONE/OXYMORPHONE SCREEN WITH PANEL

POP Begin: 10-01-2022 POP End: 09-30-2023

EIA PCP

POP Begin: 10-01-2022 POP End: 09-30-2023

FENTANYL LC/MS CONFIRMATION (URINE)

POP Begin: 10-01-2022 POP End: 09-30-2023

FENTANYL ORAL FLUID CONFIRMATION LC/MS

POP Begin: 10-01-2022 POP End: 09-30-2023

FULL DRUG SCAN (GC/MS)

POP Begin: 10-01-2022 POP End: 09-30-2023

LC/MS/MS OXYCODONE(FFL)

POP Begin: 10-01-2022 POP End: 09-30-2023

METHADONE (LC/MS)

POP Begin: 10-01-2022 POP End: 09-30-2023

OF FENTANYL(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-8 PANEL (EIA)

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-AMPH (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-BENZODIAZEPINES (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-BUPRENORPHINE(LC/MS/MS)-FFL-ORALFLUID CONFIRMATION

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-COCAINE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-METHADONE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-OPIATE (LC/MS/MS) FFL

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-PCP(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2022 POP End: 09-30-2023

OF-THC(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2022 POP End: 09-30-2023

OPIATES LC/MS (CLINICAL) (URINE)

POP Begin: 10-01-2022 POP End: 09-30-2023

ORAL 6 PANEL (EIA)

POP Begin: 10-01-2022 POP End: 09-30-2023

ORAL FLUID (O,M,C,V,T,OXY,BUP) (EIA)

POP Begin: 10-01-2022 POP End: 09-30-2023

ORAL FLUID 7 PANEL (EIA)

POP Begin: 10-01-2022 POP End: 09-30-2023

Oral Fluid 10 Panel

POP Begin: 10-01-2022 POP End: 09-30-2023

PHENOTHIAZINES (PHENERGAN)

POP Begin: 10-01-2022 POP End: 09-30-2023

RECHECK

POP Begin: 10-01-2022 POP End: 09-30-2023

TLC S2 SCREEN

POP Begin: 10-01-2022 POP End: 09-30-2023

UNTESTABLE

POP Begin: 10-01-2022 POP End: 09-30-2023

UNTESTABLE (B)

POP Begin: 10-01-2022 POP End: 09-30-2023

6 MONOACETYL MORPHINE (GC/MS)

Contract Period: Option 4 POP Begin: 10-01-2023 POP End: 09-30-2024

AMPHETAMINES (LC/MS)

POP Begin: 10-01-2023 POP End: 09-30-2024

BARBITURATES LC/MS

POP Begin: 10-01-2023 POP End: 09-30-2024

BENZODIAZEPINES (LC/MS)

POP Begin: 10-01-2023 POP End: 09-30-2024

BENZOYLECOGNINE

POP Begin: 10-01-2023 POP End: 09-30-2024

BUPRENORPHINE CONF (LC/MS)

POP Begin: 10-01-2023 POP End: 09-30-2024

CLONIDINE

POP Begin: 10-01-2023 POP End: 09-30-2024

COCAINE (LC/MS)

POP Begin: 10-01-2023 POP End: 09-30-2024

DELTA 9 THC COOH (GC/MS)

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA BUPRENORPHINE (O.F.)

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA FENTANYL SCREEN (URINE)

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA AMPHETAMINES

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA BARBITURATES

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA BENZODIAZEPINES

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA BUPRENORPHINE

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA BUPRENORPHINE WITH PANEL

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA COCAINE

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA FENTANYL with Panel (URINE)

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA METHADONE (O.F.)

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA OPIATES

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA OXYCODONE/OXYMORPHONE SCREEN WITH PANEL

POP Begin: 10-01-2023 POP End: 09-30-2024

EIA PCP

POP Begin: 10-01-2023 POP End: 09-30-2024

FENTANYL LC/MS CONFIRMATION (URINE)

POP Begin: 10-01-2023 POP End: 09-30-2024

FENTANYL ORAL FLUID CONFIRMATION LC/MS

POP Begin: 10-01-2023 POP End: 09-30-2024

FULL DRUG SCAN (GC/MS)

POP Begin: 10-01-2023 POP End: 09-30-2024

LC/MS/MS OXYCODONE(FFL)

POP Begin: 10-01-2023 POP End: 09-30-2024

METHADONE (LC/MS)

POP Begin: 10-01-2023 POP End: 09-30-2024

OF FENTANYL(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-8 PANEL (EIA)

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-AMPH (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-BENZODIAZEPINES (LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-BUPRENORPHINE(LC/MS/MS)-FFL-ORALFLUID CONFIRMATION

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-COCAINE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-METHADONE(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-OPIATE (LC/MS/MS) FFL

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-PCP(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2023 POP End: 09-30-2024

OF-THC(LC/MS/MS)-FFL ORAL FLUID CONFIRMATION

POP Begin: 10-01-2023 POP End: 09-30-2024

OPIATES LC/MS (CLINICAL) (URINE)

POP Begin: 10-01-2023 POP End: 09-30-2024

ORAL 6 PANEL (EIA)

POP Begin: 10-01-2023 POP End: 09-30-2024

ORAL FLUID (O,M,C,V,T,OXY,BUP) (EIA)

POP Begin: 10-01-2023 POP End: 09-30-2024

ORAL FLUID 7 PANEL (EIA)

POP Begin: 10-01-2023 POP End: 09-30-2024

Oral Fluid 10 Panel

POP Begin: 10-01-2023 POP End: 09-30-2024

PHENOTHIAZINES (PHENERGAN)

POP Begin: 10-01-2023 POP End: 09-30-2024

RECHECK

POP Begin: 10-01-2023 POP End: 09-30-2024

TLC S2 SCREEN

POP Begin: 10-01-2023 POP End: 09-30-2024

UNTESTABLE

POP Begin: 10-01-2023 POP End: 09-30-2024

UNTESTABLE (B)

POP Begin: 10-01-2023 POP End: 09-30-2024

36C24520Q0080

Page 1 of Page 1 of

SECTION C - CONTRACT CLAUSES

C.1 52.212-4 CONTRACT TERMS AND CONDITIONS—COMMERCIAL ITEMS (OCT 2018)

(a) Inspection/Acceptance. The Contractor shall only tender for acceptance those items that conform to the requirements of this contract. The Government reserves the right to inspect or test any supplies or services that have been tendered for acceptance. The Government may require repair or replacement of nonconforming supplies or reperformance of nonconforming services at no increase in contract price. If repair/replacement or reperformance will not correct the defects or is not possible, the Government may seek an equitable price reduction or adequate consideration for acceptance of nonconforming supplies or services. The Government must exercise its post-acceptance rights—

(1) Within a reasonable time after the defect was discovered or should have been discovered; and

(2) Before any substantial change occurs in the condition of the item, unless the change is due to the defect in the item.

(b) Assignment. The Contractor or its assignee may assign its rights to receive payment due as a result of performance of this contract to a bank, trust company, or other financing institution, including any Federal lending agency in accordance with the Assignment of Claims Act (31 U.S.C. 3727). However, when a third party makes payment (e.g., use of the Governmentwide commercial purchase card), the Contractor may not assign its rights to receive payment under this contract.

(c) Changes. Changes in the terms and conditions of this contract may be made only by written agreement of the parties.

(d) Disputes. This contract is subject to 41 U.S.C. chapter 71, Contract Disputes. Failure of the parties to this contract to reach agreement on any request for equitable adjustment, claim, appeal or action arising under or relating to this contract shall be a dispute to be resolved in accordance with the clause at FAR 52.233-1, Disputes, which is incorporated herein by reference. The Contractor shall proceed diligently with performance of this contract, pending final resolution of any dispute arising under the contract.

(e) Definitions. The clause at FAR 52.202-1, Definitions, is incorporated herein by reference.

(f) Excusable delays. The Contractor shall be liable for default unless nonperformance is caused by an occurrence beyond the reasonable control of the Contractor and without its fault or negligence such as, acts of God or the public enemy, acts of the Government in either its sovereign or contractual capacity, fires, floods, epidemics, quarantine restrictions, strikes, unusually severe weather, and delays of common carriers. The Contractor shall notify the Contracting Officer in writing as soon as it is reasonably possible after the commencement of any excusable delay, setting forth the full particulars in connection therewith, shall remedy such occurrence with all reasonable dispatch, and shall promptly give written notice to the Contracting Officer of the cessation of such occurrence.

(g) Invoice.

(1) The Contractor shall submit an original invoice and three copies (or electronic invoice, if authorized) to the address designated in the contract to receive invoices. An invoice must include—

(i) Name and address of the Contractor;

(ii) Invoice date and number;

(iii) Contract number, line item number and, if applicable, the order number;

(iv) Description, quantity, unit of measure, unit price and extended price of the items delivered;

(v) Shipping number and date of shipment, including the bill of lading number and weight of shipment if shipped on Government bill of lading;

(vi) Terms of any discount for prompt payment offered;

(vii) Name and address of official to whom payment is to be sent;

(viii) Name, title, and phone number of person to notify in event of defective invoice; and

(ix) Taxpayer Identification Number (TIN). The Contractor shall include its TIN on the invoice only if required elsewhere in this contract.

(x) Electronic funds transfer (EFT) banking information.

(A) The Contractor shall include EFT banking information on the invoice only if required elsewhere in this contract.

(B) If EFT banking information is not required to be on the invoice, in order for the invoice to be a proper invoice, the Contractor shall have submitted correct EFT banking information in accordance with the applicable solicitation provision, contract clause (e.g., 52.232-33, Payment by Electronic Funds Transfer—System for Award Management, or 52.232-34, Payment by Electronic Funds Transfer—Other Than System for Award Management), or applicable agency procedures.

(C) EFT banking information is not required if the Government waived the requirement to pay by EFT.

(2) Invoices will be handled in accordance with the Prompt Payment Act (31 U.S.C. 3903) and Office of Management and Budget (OMB) prompt payment regulations at 5 CFR part 1315.

(h) Patent indemnity. The Contractor shall indemnify the Government and its officers, employees and agents against liability, including costs, for actual or alleged direct or contributory infringement of, or inducement to infringe, any United States or foreign patent, trademark or copyright, arising out of the performance of this contract, provided the Contractor is reasonably notified of such claims and proceedings.

(i) Payment.—

(1) Items accepted. Payment shall be made for items accepted by the Government that have been delivered to the delivery destinations set forth in this contract.

(2) Prompt payment. The Government will make payment in accordance with the Prompt Payment Act (31 U.S.C. 3903) and prompt payment regulations at 5 CFR part 1315.

(3) Electronic Funds Transfer (EFT). If the Government makes payment by EFT, see 52.212-5(b) for the appropriate EFT clause.

(4) Discount. In connection with any discount offered for early payment, time shall be computed from the date of the invoice. For the purpose of computing the discount earned, payment shall be considered to have been made on the date which appears on the payment check or the specified payment date if an electronic funds transfer payment is made.

(5) Overpayments. If the Contractor becomes aware of a duplicate contract financing or invoice payment or that the Government has otherwise overpaid on a contract financing or invoice payment, the Contractor shall—

(i) Remit the overpayment amount to the payment office cited in the contract along with a description of the overpayment including the—

(A) Circumstances of the overpayment (e.g., duplicate payment, erroneous payment, liquidation errors, date(s) of overpayment);

(B) Affected contract number and delivery order number, if applicable;

(C) Affected line item or subline item, if applicable; and

(D) Contractor point of contact.

(ii) Provide a copy of the remittance and supporting documentation to the Contracting Officer.

(6) Interest.

(i) All amounts that become payable by the Contractor to the Government under this contract shall bear simple interest from the date due until paid unless paid within 30 days of becoming due. The interest rate shall be the interest rate established by the Secretary of the Treasury as provided in 41 U.S.C. 7109, which is applicable to the period in which the amount becomes due, as provided in (i)(6)(v) of this clause, and then at the rate applicable for each six-month period as fixed by the Secretary until the amount is paid.

(ii) The Government may issue a demand for payment to the Contractor upon finding a debt is due under the…